Local News

• Johnson & Johnson announces definitive agreement to acquire Mentor  Johnson & Johnson and Mentor Corporation, a leading supplier of medical products for the global aesthetic market, announced a definitive agreement whereby Mentor will be acquired for approximately $1.07 billion in a cash tender offer.
  Johnson & Johnson December 01, 2008  
• Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain  Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain.
  Eli Lilly and Company November 28, 2008  
• MedImmune receives FDA Complete Response letter on motavizumab  AstraZeneca announced that MedImmune, its wholly owned biologics business, has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) asking for additional information on motavizumab.
  AstraZeneca November 28, 2008  
• Wyeth and Progenics announce positive outcome of Phase 3 study of subcutaneous RELISTOR  Wyeth Pharmaceuticals and Progenics Pharmaceuticals announced that a phase 3 clinical study investigating RELISTOR(R) subcutaneous injection to treat opioid-induced constipation (OIC) in patients with chronic, non-cancer pain achieved statistical significance for the primary endpoints.
  Progenics Pharmaceuticals, Inc. November 26, 2008  
• FDA issues Complete Response letter for ceftobiprole  Johnson & Johnson Pharmaceutical Research & Development, announced that it received a Complete Response letter from the FDA regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.
  Johnson & Johnson November 26, 2008  
• Pfizer’s novel HIV/AIDS treatment SELZENTRY fully approved  The U.S. Food and Drug Administration has granted SELZENTRY(TM) full approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals. SELZENTRY was originally granted accelerated conditional approval in August 2007.
  Pfizer Inc. November 26, 2008  
• AstraZeneca settles US Pulmicort Respules patent litigation with Teva  AstraZeneca announced it has entered into a settlement agreement in its Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals, a wholly owned subsidiary of Teva Pharmaceuticals USA.
  AstraZeneca November 25, 2008  
• Johnson & Johnson begins tender offer to acquire Omrix  Johnson & Johnson is commencing, through a new wholly-owned subsidiary, Binder Merger Sub, a cash tender offer to purchase all outstanding shares of common stock of Omrix Biopharmaceuticals. Johnson & Johnson reported on November 24, 2008, its intent to acquire Omrix.
  Johnson & Johnson November 25, 2008  
• Merck announces first quarter 2009 dividend  The Board of Directors of Merck & Co. declared a quarterly dividend of $0.38 per share on the Company's common stock for the first quarter of 2009.
  Merck & Co., Inc. November 25, 2008  
• AstraZeneca provides update on agreement with Abraxis Biosciences  On 19 November 2008, AstraZeneca entered into an agreement with Abraxis BioScience under which, subject to the satisfaction of terms and conditions thereof, Abraxis would re-acquire exclusive rights to market ABRAXANE in the United States.
  AstraZeneca November 25, 2008  

   (next 10 articles)